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Abstract
We previously developed a method for determiningMYCN gene amplification status using
cell-free DNA fragments released from cancer cells into the blood of patients with neuroblas-
toma (NB). Here, we analyzed the relationship betweenMYCN amplification (MNA) status
and neuroblastoma prognosis. We screened serum samples from 151 patients with NB for
MNA, using real-time quantitative PCR, and compared the results withMYCN status deter-
mined using paired tumor samples. We additionally investigated whether MNA status corre-
lates with patient survival. When a cut-off value of 5 was used, serum-based MNA analysis
was found to show good sensitivity (86%) and very high specificity (95%). The sensitivities for
stage 1 and 2 might be acceptable, even though it is not as good as for stage 3 and 4 (67%
for stage 1 and 2, 92% for stage 3, and 87% for stage 4). MNA status correlated with overall
survival in our cohort of 82 patients, with survival data available (p < 0.01). The hazard ratio of
MNA status was 4.98 in patients diagnosed at less than 18months of age (95% confidence
interval, 1.00–24.78), and 1.41 (95% confidence interval, 0.63–3.14) for those diagnosed at
18 months of age or older. Serum-based MNA analysis is rapid and non-invasive compared
with tumor-basedMNA analysis, and has potential to predict tumor MNA status. There is still
a room to improve the sensitivity of the test for tumors of stages 1 and 2, nonetheless this
assay might help to determine therapeutic strategies prior to tumor biopsy, especially for
patients with a life-threatening condition, as well as for patients of less than 18months of age
whose risk-grouping and treatment allocation depends on their MNA status.
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Introduction
Patients with neuroblastoma (NB) fall into 2 clinically distinct subgroups: a low-risk sub-
group and a high-risk subgroup based on their age of onset [1], the extent of the disease [2],
pathological findings [3], and genomic changes in NB tumors. The prognosis of NB depends
on the age of onset; in addition, most NB tumors produce catecholamine metabolites. There-
fore, a screening test for NB has been designed with the aim of enabling early intervention
and consequent improvement in survival in patients with NB. This nationwide screening
system, which was launched in Japan in 1973 and later introduced in other countries [4, 5],
has facilitated the detection of NB in numerous patients of less than one year of age prior to
the overt clinical manifestation of symptoms. Consequently, the diagnosis rates of NB
sharply rose after the screening commenced; however, most patients diagnosed with NB via
screening exhibited good prognosis [6, 7]. Further observation revealed that most of the sub-
clinical tumors were occult tumors capable of spontaneously regressing or differentiating
without becoming clinically overt [8–10]. Moreover, 2 prospective studies concluded that
detection of subclinical NB by mass screening did not reduce overall mortality in patients
with this disease [11, 12]. Therefore, mass screening for NB was criticized as being “over-
diagnostic,” and the Japanese nationwide screening program for the early detection of NB
was paused in 2004. Recent efforts have focused on the development of novel, clinically use-
ful, and cost-effective NB screening systems to enable improvements in outcome for patients
with NB.
In contrast to the above findings, those of a population-based cohort study assessing the
effectiveness of the Japanese mass screening program revealed that the mortality rates of chil-
dren with NB, who were diagnosed via screening at the age of 6 months, were lower than in the
prescreening cohort [13]. These data imply that certain high-risk patients with NB may benefit
from early diagnosis (via screening) and intervention. Therefore, the development of a method
for identification of such patients within the screened cohort is desirable for improving the
effectiveness of screening programs.
The most powerful genetic prognostic factor in NB isMYCN gene amplification (MNA) sta-
tus. We, and others, have demonstrated that MNA is strongly correlated with poor prognosis
even in infantile NB [14, 15], and that the outcomes of patients with NB that exhibit MNA are
significantly worse than those that do not exhibit MNA NB patients, even in patients aged less
than 18 months [14, 15]. Therefore, for patients diagnosed with NB at less than 18 months of
age, rapid and accurate determination of MNA status is essential.
We previously developed a detection system for tumor MNA status using tumor-derived
DNA fragments extracted from patients’ sera [16]. The present study aimed to investigate the
utility of MNA status as a tool for the identification of high-risk patients with NB that may
benefit from early therapeutic intervention. We attempted to determine whether the previously
developed serum-based MNA analysis enables the identification of patients with poor progno-
sis among infantile cases in general. In addition, we investigated whether the detection of
MYCN DNA in serum, in addition to the measurement of urine catecholamine metabolites,
may be used as a secondary screening tool for infantile NB.
Materials and Methods
Subjects
We collected tumor and serum samples as well as clinical data for patients registered with tis-
sue banks at the Children’s Oncology Group in the USA, and Hiroshima University and the
Chiba Cancer Center Research Institute, both in Japan. Eligibility criteria were: 1) histologically
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confirmed NB diagnosis, 2) evaluation of MNA status by Southern blotting or interphase fluo-
rescence in situ hybridization, 3) availability of tumor and serum samples, and 4) provision of
written informed consent of patients or their parents at the time of sample collection. Data
management was conducted by an independent data center. The serum and tumor samples
were linked with clinical data at the data center and the laboratory-based investigators were
blinded to these data. This study was conducted in accordance with the Declaration of Helsinki
and the research protocol was approved by the Kyoto Prefectural University of Medicine ethi-
cal review committee.
A total of 151 tumor and serum samples were collected; 37 from patients registered at Hiro-
shima University between 1983 and 2002, 68 from patients registered at Chiba Cancer Center
Research Institute between 2001 and 2006, and 46 from patients registered at the Children’s
Oncology Group between 2000 and 2006 (Fig 1). The date of diagnosis was not available for
patients registered at the Chiba Cancer Center Research Institute. The ratios ofMYCN and
NAGK gene dosage (M/N ratios) [16] in 3 of the 151 patients could not be evaluated as no
MYCN or NAGK amplicon was detected in samples from these patients. In addition, overall
survival of 66 of the 148 patients, whose M/N ratio could be evaluated, could not be deter-
mined. Therefore, 82 patients were finally included in the study for determination of overall
survival. The MNA status of the tumors was analyzed at each respective institute.
DNA extraction from tumor and serum samples
Tumor DNA was extracted at each institute according to the standard protocol, stored at
-20°C, and used for this study under the approval of the relevant Institutional Review Boards.
The serum samples were obtained from patients prior to therapy or surgery, and were stored at
-20°C. Serum DNA was extracted as described previously [16, 17].
Fig 1. Patient disposition.
doi:10.1371/journal.pone.0161039.g001
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Real-time quantitative PCR
CirculatingMYCN gene dosage was quantitated by real-time quantitative PCR, as previously
described [16]. TheMYCN copy number of a sample of DNA was determined as the ratio of
MYCN dosage to NAGK dosage (M/N ratio). Copy numbers were expressed as the average of 2
measurements.
Statistical considerations
Planned sample size and all statistical analyses were pre-specified in the research protocol. The
planned sample size of 170 was set to obtain sensitivity and specificity narrower than ± 5%
with 95% confidence intervals (CIs), based on our previous study [16].
The primary endpoint was overall survival time, defined as the time from diagnosis to
death. Additionally, the diagnostic accuracy of the serumM/N ratio as a predictor of tumor
MNA status was evaluated. The difference in serumM/N ratio between the MNA and non-
MNA groups was assessed using the Wilcoxon rank sum test. Spearman’s rank correlation was
calculated to assess the correlation between serum and tumor M/N ratio. In order to identify
the optimal cut-off point for the M/N ratio, a receiver operating characteristic (ROC) curve
was constructed and the area under the curve (AUC) was calculated. To determine overall sur-
vival time, survival curves were derived by the Kaplan-Meier method. Performance of the
serumM/N ratio as a prognostic marker was evaluated by multivariate Cox proportional haz-
ards models. Age and tumor stage were specified in the research protocol as adjustment and
stratification factors. All the missing data were treated by complete-case analysis. Two-sided p
values of less than 0.05 were considered to represent statistical significance.
Results
Patient characteristics
Table 1 describes the clinical characteristics of the 148 eligible patients. At the time of diagno-
sis, 31 patients were younger than 18 months, 49 were between 18 months and 16 years of age,
and the date of diagnosis or birth date was not available for 68 patients of Chiba Cancer Center
Research Institute, as mentioned above. Fifty-seven of the patients exhibited MNA, and 91
patients did not exhibit MNA.
Table 1. Patient characteristics.
Characteristics No. of patients Mean SD
Age of diagnosis (day) 1064.9 1078.3
Less than 18 months 31
Over 18 months 49
Data not available 68







MYCN status Amp. 57
non-Amp 91
doi:10.1371/journal.pone.0161039.t001
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SerumM/N ratio as a predictor of tumor MNA status
The serumM/N ratio of the MNA group (n = 57, median M/N ratio = 118.27) was significantly
higher than that of the non-MNA group (n = 91, median M/N ratio 2.45; p< 0.01; S1A Fig).
These results confirm those of our previous small-scale study [16]. The ROC curve (S1B Fig)
indicates that the serum M/N ratio has excellent diagnostic power. When the cut-off value for
the serumM/N ratio was 5, the AUC was 0.911 (95% CI; 0.849–0.974), and the sensitivity and
specificity were 86% (95% CI; 74–94%) and 95% (95% CI; 88–98%), respectively. Moreover,
the serumM/N ratios were well correlated with the tumor M/N ratios (Spearman correlation
coefficient = 0.671, 95% CI; 0.570–0.751).
Next, we examined the differences in sensitivity and specificity of this assay between Inter-
national Neuroblastoma Staging System (INSS) stages. A subgroup analysis according to INSS
stage revealed no statistically significant differences in sensitivities and specificities; however,
the low statistical power, owing to the small number of patients in each group, did not enable
the detection of differences (p = 0.48 for sensitivity, p = 0.68 for specificity, chi-squared test,
Table 2). These data demonstrate that the serum M/N ratio is a specific tool for the prediction
of tumor MNA status in patients with NB, regardless of tumor stage, though the sensitivity in
stage 1/2 NB showed lower than in stage 3 or 4 NB.
SerumM/N ratio as a prognostic marker for NB in patients less than 18
months of age
The correlation between serumM/N ratio and clinical outcome was analyzed in 82 cases for
which clinical data were available. As anticipated by the high sensitivity of this serum based
MNA analysis, univariate analyses revealed that patients with MNA, as determined based on
their serumM/N ratio, exhibited significantly worse overall survival than patients without
MNA (hazard ratio: 2.50; 95% CI; 1.22–5.13, p< 0.01, Fig 2A). A subgroup analysis revealed
that serumM/N ratio also had significant prognostic power when limited to cases diagnosed at
less than 18 months of age. However, in the subset of patients older than 18 months, we did
not observe a significant difference in survival between patients with and without MNA (Fig
2B, Table 3); these findings were consistent with those of previous studies of the prognostic
power of tumor MNA status [18]. These data suggest that serumM/N ratio may be utilized as
a surrogate prognostic marker for NB in patients less than 18 months of age.









Stage (INSS) Serum M/N ratio
Stage 1 and 2 less than 5.0 36 2 67% 95%
over 5.0 2 4 (22–96%) (82–99%)
Stage 3 less than 5.0 12 1 92% 86%
over 5.0 2 11 (62–100%) (57–98%)
Stage 4 less than 5.0 32 5 87% 97%
over 5.0 1 33 (72–96%) (84–100%)
Stage 4s less than 5.0 6 0 100% 100%
over 5.0 0 1 (3–100%) (54–100%)
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Discussion
Our results show that serum-based analysis of MNA has sufficiently high sensitivity and
remarkably high specificity for detecting the status of amplification of theMYCN gene in
serum samples. The serumM/N ratio of patients with NB has considerable prognostic value,
especially in patients aged less than 18 months, confirming that MNA status is useful as a prog-
nostic biomarker even in infantile NB [14, 15]. Previous nationwide mass screening programs
for NB have revealed that most cases of localized infantile NB showed good prognosis [5–7, 11,
12] and that de-escalated therapies were justified in such patients. Even after suspension of
screening in Japan in 2004, physicians currently recommend conservative therapies, including
surgery alone or even expectant observation, following tumor biopsy in children with NB diag-
nosed at less than one year of age [19–21]. Although this expectant observation strategy was
initially applied to patients with perinatally detected adrenal masses, this strategy is now being
extended to other young patients with localized NB [21]. However, this approach may lead to
misclassification of patients, especially in infantile cases with MNA-associated NB, and precise
evaluation of prognostic factors using tumor markers obtained by less invasive techniques are
desirable for such patients. The previously developed serum assay should be useful for evalua-
tion of prognosis in this group. In addition to the disease stage, we propose that serum MNA
status should be evaluated in newly diagnosed infantile patients with NB exhibiting high
Fig 2. Kaplan-Meier survival curves for 82 patients and correlation between (a) serumM/N ratio and age of diagnosis and (b) serumM/N
ratio and overall survival rate.
doi:10.1371/journal.pone.0161039.g002
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urinary levels of catecholamine. In patients with NB, who exhibit localized tumors and serum
M/N ratios of less than 5, a good prognosis is likely and expectant observation would be justi-
fied. However, we would recommend that patients whose serumM/N ratios are higher than 5,
even infants with localized tumors, undergo tumor biopsy to determine the precise risk
classification.
In patients older than 18 months, we did not observe significant difference in survival
between patients with and without MNA, although there was no deviation in MNA status in
patients older than 18 months. In these older patients, the tumor may have acquired genetic
aberrations besides MNA that increased the likelihood of a poor outcome [22–28]. We previ-
ously developed a serum-based assay system for the detection of promoter methylation status
or chromosomal loss of heterozygosity, both of which are associated with poor prognosis in
NB [17, 29].
In the present cohort, 5 of the 57 positive cases were false positives and 8 of the 91 negative
cases were false negatives. In 3 of the 5 false-positive cases, in which the serumM/N ratio
appeared to be high, the MNA status of the tumor was negative. Further, the serumM/N ratios
were well above 5 in 3 of the false positive cases (data not shown). Although the reason for this
discrepancy is unknown, it may be attributable to the normal biological heterogeneity of NB
tumors and/or an insufficient number of tumor samples. Therefore, we propose that, when the
serumM/N ratio of a patient with non-MNA-associated NB is determined to be high, the
serumM/N ratio should be carefully re-evaluated, or the biopsy sample should be re-examined
for sufficient amount of tumor tissue or homogeneity.
In the 8 false-negative cases, in which the serumM/N ratio was below 5, the MNA status of
the tumor was positive. This represents a serious limitation in the potential utility of serumM/
N ratio as a prognostic marker, as false-negative results may lead to therapeutic abstention in
patients with MNA-positive tumors. A possible reason for this discrepancy is that the sensitiv-
ity of serum-based determination of MNA status may be lower in patients with locoregional
NB [30]. Indeed, our data suggest a lower sensitivity for stages 1 and 2 (Table 2), although the
number of patients in each group did not allow sufficient statistical power to detect significant
differences. The lower sensitivity in patients with locoregional NB may be attributable to (1)
the smaller quantity of DNA fragments released from a small tumor burden, (2) an apparent
reduction in M/N ratio due to tumor heterogeneity, or (3) low-quality serum samples in which
the DNA stability is affected. We speculate that one of the most likely reasons for low serum
M/N ratios in the present study was poor quality of the serum samples, which represents the
major limitation of this retrospective study. The collected sera were not always processed
immediately, and therefore may have become contaminated with DNA fragments from lysed
Table 3. Subgroup analysis for prognostic impact of serumM/N ratio according to age of diagnosis.
No. of patients Hazard ratio 95% CI p-value Interaction p-value
Age less than 18 months
Serum M/N ratio less than 5.0 25 1 - - - -
Serum M/N ratio over 5.0 6 4.98 1.00 24.78 0.05 -
Age over 18months
Serum M/N ratio less than 5.0 27 1 - - - -
Serum M/N ratio over 5.0 22 1.41 0.63 3.14 0.41
0.08
CI = conﬁdence interval
Two patients were excluded as their ages were not known.
doi:10.1371/journal.pone.0161039.t003
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leukocytes. Contamination of serum with DNA from normal tissue dilutes tumor-derived
DNA fragments and reduces the serumM/N ratio [16]. Indeed, DNA fragments from leuko-
cytes may have been released during storage, contaminating the serum sample and affecting
the accuracy of measurement of serumM/N ratios (S3 Fig). In order to determine the serum
MYCN status accurately, contamination due to the presence of normal cells/tissue should be
avoided by carefully removing these cells from the serum by high-speed centrifugation or filtra-
tion as soon as possible after collection of the blood sample [16]. Moreover, sera must be han-
dled promptly and appropriately and banked using a standardized method; of the 49 samples
that were promptly and appropriately handled, both sensitivity and specificity of detection of
tumor MNA status was 100% (S2 Fig). We believe that technical progress, for example a highly
effective method to purify the tumor-released DNA fragments from serum and to keep the sta-
bility of the DNA fragments in serum, could be made regarding this problem.
A partial discrepancy was observed between the findings of our previous study [30] and the
present data, particularly with regard to the sensitivity of serum MNA status in patients with
low-stage NB. Combaret and colleagues, who first identified theMYCN gene in the sera of
patients with NB, retrospectively analyzed the serum M/N ratios using stored serum samples
from such patients. Their findings showed that the sensitivity of serumMNA status depends
on the NB stage and is lower for patients with locoregional NB [30]. The authors analyzed 10
serum samples obtained at diagnosis from patients with MNA-associated NB at INSS stages 1
or 2, and 16 serum samples from patients with MNA-associated NB at INSS stage 3. They
revealed that only one of 10 patients with stage 1 or 2 disease, and 12 of the 16 patients with
stage 3 disease showed high levels of circulatingMYCN DNA (10% and 75% sensitivity, respec-
tively). In contrast, our data indicated a sensitivity of 67% for detection of patients with stage 1/
2 NB. As both studies used the same detection method [16] and incidentally used the same cut-
off value of 5, this discrepancy may be attributed to differences in the amount and purity of
MYCN sequences retrieved from the serum of patients with stage 1/2 disease. The concentra-
tion of DNA fragments in the sera of patients with metastatic tumors was significantly higher
than in those of patients with localized tumors [31], although tumor-derived cell-free DNA
was also found in the serum of patients with localized, early-stage tumors [16, 17, 32]. There-
fore, the degradation of serum DNA or contamination with DNA fragments from normal tis-
sue would exert a greater impact on accuracy of diagnosis of locoregional NB than on
metastatic NB. The translation of our findings into the clinic would require the development of
specialized devices or kits in order to reduce levels of degradation or contamination resulting
from the presence of tumor-derived DNA fragments in serum samples, and for improved sen-
sitivity of detection of MNA status. The additional use of other serum-based biomarkers, such
as loss of 11q or aberrant DNA hypermethylation, in combination with the present method,
may be useful for accurate identification of high-risk patients with NB.
Conclusion
The application of the present findings to population-screening programs requires improve-
ment in the sensitivity of the detection method especially for the patients with low-stage NB;
however, the present assay should be useful for the design of therapeutic strategies for patients
with NB prior to a tumor biopsy, especially for patients with a life-threatening condition and
those less than 18 months of age, whose risk grouping and treatment allocation depends on
their MNA status. The advantages of this method for preoperative evaluation of MNA status
are that it (1) benefits patients with NB, including children, by enabling rapid determination of
MNA status prior to biopsy or surgical resection, (2) involves no procedures that are laborious
for pediatric surgeons and oncologists or hazardous for patients, and (3) requires only 200 μL
SerumMYCN Status Predicts Neuroblastoma Prognosis
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of serum and approximately 4 h to analyze, making it a relatively low-cost procedure suitable
for all patients with high concentrations of urine catecholamine metabolites. Screening strate-
gies based on a combination of serum-based evaluation of MNA status and other biological
assays, which would compensate for “false negative” cases of diagnosis via serum-based analy-
sis of MNA status alone, represent a potentially useful next-generation screening tool for iden-
tification of high-risk patients with NB, even in infantile cases.
Supporting Information
S1 Fig. Sensitivity and specificity of serumM/N ratio. (a) Box plot of serumM/N ratio in
patients withMYCN amplification (MNA)- and non-MNA-associated neuroblastoma. The
serumM/N ratio was significantly higher in the MNA group (n = 57; median M/N ratio:
118.27; range: 1.09–3889.17) than in the non-MNA group (n = 91; median M/N ratio: 2.45;
range: 0.63–129.23; p< 0.01, Mann-Whitney U test). (b) Receiver operating characteristic
curve for sensitivity and specificity of serumM/N ratio: the area under the curve was 0.911
(95% confidence interval (CI); 0.849–0.974), and the sensitivity and specificity were 86% (95%
CI; 74–94%) and 95% (95% CI; 88–98%), respectively, when the cut-off value for the serumM/
N ratio was 5.
(PDF)
S2 Fig. SerumM/N ratios measured immediately after serum collection. Sera of 59 patients
with neuroblastoma were collected prior to tumor biopsy. Subsequently, contaminating white
blood cells were immediately removed to prevent their interference with determination of
DNA-basedMYCN amplification (MNA) status. The serumMYCN/NAGK (M/N) ratio was
assessed prospectively for all cases; when the ratio was 5 or greater, this was interpreted as
MNA-positive. Following the determination of serumM/N ratio, each biopsied tumor sample
was assessed by interphase fluorescence in situ hybridization (I-FISH). Among the 59 cases, 10
cases could not be evaluated due to lack of tumor samples. In the other 49 cases, in which
tumorMYCN status could be evaluated, 13 cases exhibited MNA and 36 cases did not. Serum
M/N status of all 13 MNA cases was greater than 5.0, while that of the other 36 non-MNA
cases were less than 5.0.
(PDF)
S3 Fig. Contamination of DNA fragments from lysed leukocytes. Leukocytes (5 × 103) were
added to 200 μl of IMR32 NB cell (MYCN gene amplified) culture supernatant and stored at
4°C. Then, leukocytes were removed from the samples by centrifugation (15000rpm, 10min at
4°C) immediately as well as after 1, 4, 7, and 14 days, and the M/N ratios were calculated. For
leukocytes removed immediately from the supernatant, the M/N ratio was almost equivalent to
that of non-contaminated samples, whereas the M/N ratio was greatly reduced in samples
stored, without leukocyte removal, for over 4 days.
(PDF)
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